CERo Therapeutics Holdings, Inc.
CERO
$0.04
$0.008.70%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.76% | 0.22% | 41.99% | 56.67% | 136.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.05% | 14.93% | 37.86% | 74.10% | 115.72% |
| Operating Income | -23.05% | -14.93% | -37.86% | -74.10% | -115.72% |
| Income Before Tax | -139.87% | -43.61% | -91.22% | -58.57% | -16.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -139.87% | -43.61% | -91.22% | -58.57% | -16.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.87% | -43.61% | -91.22% | -58.57% | -16.22% |
| EBIT | -23.05% | -14.93% | -37.86% | -74.10% | -115.72% |
| EBITDA | -24.68% | -16.37% | -40.18% | -78.44% | -123.60% |
| EPS Basic | 68.84% | 49.20% | -103.11% | -170.49% | -338.07% |
| Normalized Basic EPS | 83.04% | 65.27% | -267.73% | -251.34% | -- |
| EPS Diluted | 68.84% | 49.20% | -103.11% | -170.49% | -338.07% |
| Normalized Diluted EPS | 83.04% | 65.27% | -267.73% | -251.34% | -- |
| Average Basic Shares Outstanding | 16,874.12% | 8,526.95% | 10,900.00% | 9,612.14% | -- |
| Average Diluted Shares Outstanding | 12,794.74% | 5,276.84% | 1,305.60% | 675.56% | -76.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |